Body Vision’s AI-powered LungVision image system earned a place in Vizient’s innovative technology program.
Vizient signed an innovative technology contract with Body Vision Medical for its AI-powered LungVision image guidance system.1 Hospital experts on Vizient’s customer-led council recommended the system based on its potential to improve healthcare.
LungVision is designed to work with C-arm fluoroscopes to produce real-time images that doctors can use to identify and locate lung nodules, which is helpful in diagnosing and treating lung diseases such as lung cancer. Vizient’s innovative technology program will provide Body Vision Medical with contracting and marketing opportunities, along with visibility on Vizient’s online forum.
In a press release, Body Vision Medical’s vice president of sales and market development Jon Ulvestad said, “We are honored by Vizient's recognition of LungVision® as an innovative technology. LungVision's combination of real-time imaging, augmented fluoroscopy, and image-guided navigation is functionally unique in the navigational bronchoscopy space. The fact that these capabilities are found in a system that has been proven to provide superior clinical outcomes, helps reduce radiation exposure, is compatible with any existing bronchoscopy setup, and is cost-effective enough to be a viable option for medical institutions of all types is truly game-changing. Vizient's contract award makes it easier for its customers to access this innovative technology and improve their ability to definitively diagnose lung patients."
In the same press release, Kelly Flaharty, senior director of contract services for Vizient, said, “A product receives this type of contract when it demonstrates a unique quality that differentiates it from other products on the market. Our customer-led council determined that Body Vision Medical's LungVision met this standard and recognizes its potential to improve quality outcomes."
Body Vision Medical also recently announced that Matt Baker would serve as its new CEO. Baker, who previously served as the company’s chief operating officer, is replacing David Webster.2
In a press release issued at the time, Body Vision Medical’s chairman of the board Yuval Bar-Gil said, “We extend our heartfelt gratitude to David Webster for his exceptional leadership and unwavering dedication during his tenure as CEO. David's visionary guidance has put the company in a strong financial and commercial position and we are confident in Matt's ability to continue the company's growth and excellence in all aspects during this transitional period and beyond."
In March, Body Vision also announced that its LungVision system had successfully been validated with FUJIFILM Healthcare America Corporations line of C-arms.3
In a press release, Webster (who was serving as CEO of Body Vision at the time), said, “This validation further demonstrates the power of an AI-driven imaging platform like LungVision™ that enables physicians to agnostically leverage our image-guided navigation and real-time imaging with the bronchoscopy platform and C-arm of their choice. Fujifilm's C-arms demonstrate very innovative and competitive thinking and pairing them with LungVision™ helps to create a complete image-guided navigational bronchoscopy solution for targeting the most challenging lesions."
In the same press release, FUJIFILM’s director of strategic marketing for diagnostic imaging Rob Fabrizio said, “Fujifilm is committed to delivering innovative, best-of-breed solutions focused on enhancing patient experience while streamlining the procedural workflow for healthcare providers. We're elated to see the successful validation of our C-arm platforms with Body Vision's leading LungVision™ system to synergistically provide the visualization needed by bronchoscopists during navigation bronchoscopy.”
Body Vision Medical Receives Innovative Technology Contract from Vizient for LungVision. Body Vision Medical. July 9, 2024. https://www.prnewswire.com/news-releases/body-vision-medical-receives-innovative-technology-contract-from-vizient-for-lungvision-302191339.html
Body Vision Medical Announces Departure of David Webster as CEO and Appoints Matt Baker as Successor. Body Vision Medical. July 2, 2024. Accessed July 9, 2024. https://www.prnewswire.com/news-releases/body-vision-medical-announces-departure-of-david-webster-as-ceo-and-appoints-matt-baker-as-successor-302187445.html
Body Vision Medical Announces Successful Validation of LungVision™ System with Fujifilm's Range of Surgical C-arms. Body Vision Medical. March 5, 2024. Accessed July 9, 2024. https://www.prnewswire.com/news-releases/body-vision-medical-announces-successful-validation-of-lungvision-system-with-fujifilms-range-of-surgical-c-arms-302079954.html
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.